Steven D. Averbuch

Steven D. Averbuch, M.D. is an industry veteran with more than 35 years in oncology drug development, more than a decade in biomarker and drug diagnostic co-development, and has contributed to multiple drug and companion diagnostic approvals in the U.S. and other major markets.

During his tenure at Bristol-Myers Squibb, he spearheaded the Pharmaco diagnostics Center of Excellence, established in 2008, which led to the application of BMS’ precision medicine strategy across all therapeutic areas. Dr. Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine and served as the Head of Early GlobalClinical Research at Bristol-Myers Squibb, where he was responsible for early asset development strategy and execution of all Phase 2 oncology programs.

Dr. Averbuch served in leadership roles atMerck Research Laboratories for oncology clinical research and at AstraZenecafor oncology drug development.